Finance

Lists
Why is GOSS down 2.40%?
Dive Deeper
GOSS:NASDAQ
Gossamer Bio Inc
$10.97
-2.40%
(-0.27) 1D
Nov 13, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GOSS...
Open
$11.19
High
$11.40
Low
$10.60
Mkt. cap
67.10M
Avg. vol.
210.44K
Volume
124.14K
52-wk high
$309.20
52-wk low
$8.30
EPS
-$35.48
Beta
2.28
Shares outstanding
6.12M
No. of employees
161
Open
$11.19
High
$11.40
Low
$10.60
Mkt. cap
67.10M
Avg. vol.
210.44K
Volume
124.14K
52-wk high
$309.20
52-wk low
$8.30
EPS
-$35.48
Beta
2.28
Shares outstanding
6.12M
No. of employees
161
News stories
From web sources and news partners
About Gossamer Bio Inc
CEO-
Employees161
Founded2015
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitegossamerbio.com
Analyst ratings
Based on 3 analysts giving stock ratings to GOSS in the past 3 months
Buy
Buy
2
Hold
1
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for GOSS in the last 3 months.
Highest
Current $10.97
$160.00 (+1,358.52%)
Average
$125.00 (+1,039.47%)
Lowest
$90.00 (+720.42%)
Analyst
Recommendation
Action
Price target
Projected
Date
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
$90.00
+720.4%
11/13/2026
Unknown Analyst
Guggenheim
Hold
Maintained
-
-
11/11/2026
Andreas Argyrides
Chardan Capital
Buy
Initiated
$160.00
+1,358.5%
10/13/2026
Laura Chico
Wedbush
Hold
Maintained
$80.00
+629.3%
08/14/2026
Eliana Merle
Barclays
Sell
Maintained
$22.40
+104.2%
07/28/2026
Joseph Schwartz
Leerink Partners
Buy
Upgraded
$80.00
+629.3%
07/27/2026
Olivia Brayer
Cantor Fitzgerald
Hold
Downgraded
-
-
03/20/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$15.00
+36.7%
03/18/2026
Paul Choi
Goldman Sachs
Hold
Downgraded
$0.50
-95.4%
02/24/2026
Last report
Nov 10, 2026
Fiscal period
Q3 2026
$0.44 / -$3.93
+111.25%beat
Revenue / Est. (USD)
38.43M / 12.16M
+216.00%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
13.80M
16.96M
9.24M
38.43M
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
48.94M
43.08M
26.41M
18.83M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.90M
18.75M
8.90M
9.64M
Operating expense
59.84M
61.82M
35.31M
28.46M
Total operating expenses
59.84M
61.82M
35.31M
28.46M
Operating income
-46.04M
-44.87M
-26.07M
9.97M
Other non operating income
-3.46M
603.00K
1.56M
-53.20M
EBT including unusual items
-47.33M
-46.66M
16.90M
-48.07M
EBT excluding unusual items
-51.80M
-46.66M
-26.95M
-45.30M
Income tax expense
-88.00K
-
-
-
Effective tax rate
0.19%
-
-
-
Other operating expenses
-
-
-
-
Net income
-47.24M
-46.66M
16.90M
-48.07M
Net profit margin
-342.33%
-275.22%
182.94%
-125.09%
Earnings per share
-16.80
-16.00
-8.17
0.44
Interest and investment income
447.00K
354.00K
268.00K
400.00K
Interest expense
-2.75M
-2.76M
-2.70M
-2.46M
Net interest expenses
-2.30M
-2.40M
-2.44M
-2.06M
Depreciation and amortization charges
-
-
-
-
EBITDA
-46.03M
-44.86M
-26.07M
9.97M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps